Method and composition for hyperthermally treating cells

Patent metadata

Field	Value
Publication number	US-9393396-B2
Application number	US-201514869051-A
Country	US
Kind code	B2
Filing date	Sep 29, 2015
Priority date	Feb 14, 2002
Publication date	Jul 19, 2016
Grant date	Jul 19, 2016

Abstract

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

First claim

What is claimed is:

1. A method using hyperthermal therapy for at least one of delivery of a therapeutic agent to a cell in a patient in need thereof, the method comprising the steps of:
providing a targeted nanoparticle-agent to form a nanoparticle-agent-cell complex at a site,
thereafter exposing the site to an energy source under conditions sufficient to achieve a temperature of the complex, for about 1 femtosecond to about 15 minutes, the temperature sufficient result in agent release from the complex to the cell by at least one of
rupture of cellular membranes of cells in contact with or proximate to the nanoparticles, or
formation of holes or pores in the cellular membrane;

thereafter assessing the acoustic sound produced from the nanoparticle at the site and,
correlating the acoustic sound with the presence or absence of viable cells at the site by photoacoustic imaging and/or ultrasound spectroscopy.

2. The method of claim 1 where the therapeutic agent is at least one of a gene or a non-gene therapeutic agent, and where the agent is a gene the gene replaces or corrects a genetic defect in the cell.

3. The method of claim 2 where the therapy is applied to a patient with cancer.

4. The method of claim 3 where the agent is an anti-cancer agent, a tumor suppressor gene, and combinations thereof.

5. The method of claim 1 where the hyperthermal therapy is applied to the patient for general or en masse treatment of an organ or body region.

6. The method of claim 1 where hyperthermal therapy is applied for a duration between one femtosecond to one second.

7. The method of claim 1 where hyperthermal therapy achieves a temperature of at least 60° C.

8. The method of claim 1 further comprising administering nanoparticles coated with a thermosensitive polymer to the patient to verify that the nanoparticles are in contact with the appropriate tissue, including circulating or non-circulating cells, and using a photoacoustic unit to achieve a temperature of 37° C. to 43° C. to release the agent attached to the nanoparticles.

9. The method of claim 1 resulting in damaged cells or damaged exosomes, and further comprising quantitating at least one of the resultant damaged cells or damaged exosomes to assess efficacy.

10. The method of claim 9 where quantitating is by a patient wrist band counter or by a patient neck collar counter.

11. The method of claim 1 where a complex of a piezoelectric nanoparticle and a gene is administered to a patient, and an externally-positioned ultrasound source activates the complex to control cell polarization, the method capable of complex activation in the absence of light penetration.

12. The method of claim 1 where the nanoparticles are selected among a plurality of quantum dots, hybrid quantum dots, non-quantum dot nanoparticles, nanoparticle types, nanoparticle components, nanoparticle complexes, nanowires, nanoshells, nanorods, caged nanoparticles, nanocrystals, nanotubes, nanobots, and nanoparticle compositions, non-magnetic, magnetic, paramagnetic, diamagnetic, supramagnetic, non-magnetic, piezoelectric, liposomes, dendrimers, and combinations thereof.

13. The method of claim 1 where the nanoparticles comprise compositions selected from the group consisting of organic, non-organic, metallic, non-metallic, silver, lanthanide, cerium, gold, zinc, silicon, perovskite, ceramic, plastic, gallium/arsenide, cadmium/selenium, copper/indium/gallium/selenide, zinc sulfide, indium/gallium/phosphide, gallium arsenide, indium/gallium nitride, a nanocrystal and a metal, mesoporous carbide-derived carbon, iron oxide nanoparticles with gold, graphene oxide, mesoporous silicon nanostructures, particles of semiconductor/metal and semiconductor/semiconductor hetero-junctions, biocompatible short peptides of naturally occurring amino acids that have the optical and electronic properties of semiconductor nano-crystals, graphene quantum dots, graphene-oxide quantum dots, graphene-zinc oxide quantum dots, graphene-zinc oxide quantum nanowires, carbon nanotubes, carbon-based skeletal-type nanostructures, fullerenes, bucky balls, micelles, micelle-like structures, liposomes, dendrimers, aptamers, single-stranded deoxyribonucleic acid- or ribonucleic acid-oligonucleotide aptamer-conjugated or modified nanoparticles, dendrimers including poly(amidoamine) (PAMAM), poly(amidoamine-organosilicon) (PAMAMOS), poly(propyleneimine) (PPIO), tecto, multilingual, chiral, hybrid, amphiphilic, Frechet-type dendrimers, liposome-PEG nanoparticles, micellar polymeric platform nanoparticles, L-adenine nanoparticles, L-lysine nanoparticles, PEG-deaminase nanoparticles, polycyclodextrin nanoparticles, polyglutamate nanoparticles, calcium phosphate nanoparticles, antibody-enzyme conjugated nanoparticles, polymeric lipid hybrid nanoparticles, nanoparticles containing a combination of two-three elements such as gold, gold-iron oxide, iron-zinc oxide, metallic nanoparticles, polylacticglycolic acid nanoparticles, ceramic nanoparticles, plasmonic nanoparticles, silica nanoparticles, silica crosslinked block polymer micelles, albumin-based nanoparticles, albumin-PEG nanoparticles, dendrimer attached magnetic or non-magnetic nanoparticles, graphene/zinc oxide (ZnO) and reduced graphene oxide, plasmonic nanoparticles coated with reduced graphene oxide, dextran-reduced graphene oxide, and combinations thereof.

14. The method of claim 1 where the agent is at least one gene selected from the group consisting of genes involved in cell membrane polarization and depolarization, genes encoding opsin family genes, genes encoding neurotransmitters, genes encoding regulatory proteins, genes encoding products for synthesis or inhibition of a therapeutic protein, tumor suppressor genes, therapeutic genes, defective genes, genes that have an stimulatory action in response to light or ultrasound, and combinations thereof.

15. The method of claim 1 where the energy types to activate the nanoparticles is selected from the group consisting of electromagnetic radiation, visible light, invisible light, alternating magnet, reversible magnet, and combinations thereof.

16. The method of claim 1 further comprising administering a clustered regularly interspersed palindromic repeats (CRISPR) with the nanoparticles for gene repair, gene editing, and combinations thereof.

17. The method of claim 1 further comprising providing a nanoparticle associated with a member of specific binding pair, a cellular receptor-agonist or antagonist pair, an enzyme-substrate pair, and/or an antibody-antigen pair, a virus, or virus like particles (VLP).

18. The method of claim 1 further comprising providing a nanoparticle associated with a virus like particle resulting in an enhanced immune therapy to a tumor cell antigen in the absence of an adjuvant.

19. The method of claim 1 further comprising providing a nanoparticle with a biocompatability enhancing coating.

20. The method of claim 19 where the coating is a biocompatible polymer selected from the group consisting of biotin, streptavidin, (poly)ethylene glycol, chitosan, cell penetration peptide (CPP), arginine CPP, and combinations thereof.

21. The method of claim 1 where the nanoparticle size ranges from 1 nm to greater than 999 nm.

22. The method of claim 1 where the gene is an opsin family gene, and the energy frequency provided is selected from the group consisting of
>30 Hz with repeated pulses resulting in decreased cellular survival due to enhanced cell vulnerability to t

Assignees

• Peyman Gholam A

Inventors

• Peyman Gholam A

Classifications

• A61B18/18

  by applying electromagnetic radiation, e.g. microwaves · CPC title

• A61B2090/378

  using ultrasound · CPC title

• A61N2/002

  in combination with another treatment · CPC title

• A61N2/02

  using magnetic fields produced by coils, including single turn loops or electromagnets (A61N2/12 takes precedence) · CPC title

• A61B2017/00106

  ultrasonic · CPC title